JAZZ - Jazz Pharmaceuticals PLC Stock Price, Fair Value and News

$106.04+2.66 (+2.57%)

Delayed as of 23 Apr 2025, 10:07 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

JAZZ Price Action

Last 7 days

0.5%

Last 30 days

-25.5%

Last 90 days

-14.4%

Trailing 12 Months

-5.0%

JAZZ RSI Chart

JAZZ Valuation

Market Cap

6.3B

Price/Earnings (Trailing)

11.21

Price/Sales (Trailing)

1.54

EV/EBITDA

12.16

Price/Free Cashflow

4.62

JAZZ Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

JAZZ Fundamentals

JAZZ Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

7.53%

Rev. Growth (Qtr)

3.15%

JAZZ Earnings

Earnings (TTM)

560.1M

Earnings Growth (Yr)

102.98%

Earnings Growth (Qtr)

-11.13%

JAZZ Profitability

EBT Margin

11.56%

Return on Equity

13.68%

Return on Assets

4.66%

Free Cashflow Yield

21.63%

JAZZ Investor Care

Buy Backs (1Y)

2.59%

Diluted EPS (TTM)

8.68

JAZZ Alerts

1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.8B	3.9B	4.0B	4.1B
2023	3.7B	3.8B	3.8B	3.8B
2022	3.3B	3.5B	3.6B	3.7B
2021	2.4B	2.6B	2.9B	3.1B
2020	2.2B	2.2B	2.3B	2.4B
2019	2.0B	2.0B	2.1B	2.2B
2018	1.7B	1.8B	1.9B	1.9B
2017	1.5B	1.5B	1.6B	1.6B
2016	1.4B	1.4B	1.4B	1.5B
2015	1.2B	1.3B	1.3B	1.3B
2014	923.1M	1.0B	1.1B	1.2B
2013	679.7M	763.7M	820.4M	872.4M
2012	323.9M	383.6M	485.8M	586.0M
2011	272.3M	272.3M	272.3M	272.3M
2010	164.4M	200.4M	236.3M	272.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

CEO	Mr. Bruce C. Cozadd
WEBSITE	jazzpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	2800

Jazz Pharmaceuticals PLC Frequently Asked Questions

What is the ticker symbol for Jazz Pharmaceuticals PLC? What does JAZZ stand for in stocks?

JAZZ is the stock ticker symbol of Jazz Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jazz Pharmaceuticals PLC (JAZZ)?

As of Tue Apr 22 2025, market cap of Jazz Pharmaceuticals PLC is 6.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JAZZ stock?

You can check JAZZ's fair value in chart for subscribers.

Is Jazz Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether JAZZ is over valued or under valued. Whether Jazz Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Jazz Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAZZ.

What is Jazz Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 22 2025, JAZZ's PE ratio (Price to Earnings) is 11.21 and Price to Sales (PS) ratio is 1.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAZZ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Jazz Pharmaceuticals PLC's stock?

In the past 10 years, Jazz Pharmaceuticals PLC has provided -0.059 (multiply by 100 for percentage) rate of return.